2 results
Approved WMOCompleted
* to describe the safety profile for qW, q2W and q3W regimens. * to determine the Maximum Tolerated Dose (MTD), if achieved (all regimens)* to describe the pharmacokinetics (PK) of single-agent RO6895882. Substudy BP28920/IMGThe study is designed to…
Approved WMOCompleted
The aim of this study is to determine NET availability in patients with neurodegenerative diseases to characterize NA system degeneration in people with Alzheimer's disease, Parkinson's disease (with and without dementia) and with…